Abstract 203P
Background
The immunosuppressive tumor microenvironment (TME) appears to be the main challenge against cancer patients receiving benefits from PD-1/PD-L1-targeting immune checkpoint inhibitors (ICIs), and IL-33/ST2 signaling pathway fulfills critical roles in the TME. However, it remains uncertain whether IL-33 limits the therapeutic efficacy of anti-PD-L1 treatment.
Methods
Cellular and molecular mechanisms of the IL-33/ST2 on anti-PD-L1 treatment in lung cancer were assessed using RNA-seq, scRNA-seq, IB, and IF. A sST2-Fc fusion protein was constructed to target IL-33 and combined with an anti-PD-L1 antibody atezolizumab in lung tumor models. Based on this, bifunctional fusion proteins were generated to block IL-33 in tumors specifically targeting PD-L1. The underlying mechanisms of dual targeting of IL-33 and PD-L1 were revealed using RNA-seq, scRNA-seq, FACS, and IF.
Results
After anti-PD-L1 administration, tumor-infiltrating ST2+ regulatory T cells (Tregs) were elevated. Blocking IL-33/ST2 signaling with sST2-Fc fusion protein potentiated the antitumor efficacy of the PD-L1 antibody by boosting CD8+ T cell responses. Bifunctional fusion protein anti-PD-L1-sST2 demonstrated superior antitumor efficacy compared to combination therapy, not only inhibited tumor progression and extended survival, but also provided long-term protective antitumor immunity. Mechanistically, the superior antitumor activity of targeting both IL-33 and PD-L1 was due to a reduction in immunosuppressive factors, such as Tregs and exhausted CD8+ T cells, while increasing tumor-infiltrating cytotoxic T lymphocytes.
Conclusions
This study demonstrated that IL-33/ST2 is involved in the immunosuppression mechanism of PD-L1 antibody therapy. Blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce a potent antitumor effect. These findings highlight the potential therapeutic strategies for tumor treatment by simultaneously targeting IL-33 and PD-L1.
Legal entity responsible for the study
Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
Resources:
Abstract
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
Resources:
Abstract
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
Resources:
Abstract
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
Resources:
Abstract
36P - Exploring the role of soluble B7-H3 (sB7-H3) as a biomarker to predict the clinical benefit and/or the occurrence of immune related adverse events (irAEs) in advanced cancer patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Luigi Liguori
Session: Poster Display session
Resources:
Abstract
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
Resources:
Abstract
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
Resources:
Abstract
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
Resources:
Abstract
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
Resources:
Abstract
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session
Resources:
Abstract